54 results about "Beta globulins" patented technology

The invention discloses a gonococcus, chlamydia trachomatis and ureaplasma urealyticum detection kit. The detection kit comprises a gene chip (1) and various primers (2), wherein the gene chip carries (i) nucleotide probes of different pathogens, (ii) a biotin point-labeled DNA (deoxyribonucleic acid) sequence and (iii) a DNA sequence carrying beta-globulin encoding part; the nucleotide probes are a sequence of SEQ ID Nos:1-3 or a sequence complementary to SEQ ID Nos:1-3; the biotin point-labeled DNA sequence is SEQ ID No.4; the DNA sequence carrying beta-globulin encoding part serving as an internal control point is SEQ ID No.5; and various primers are used for amplifying the DNA sequences in a clinical sample, and have DNA sequences of SEQ ID Nos.6-11. The kit can quickly and accuratelydetect infections of gonococcus, chlamydia trachomatis and ureaplasma urealyticum, and has magnificent meaning to pathogen detection.

The invention discloses a genetic testing kit for infected bacteria in cerebrospinal fluid. The genetic testing kit comprises (1) a gene chip and (2) a primer, wherein the gene chip is provided with a. a probe used for detecting 10 bacterial colonies, b. a DNA (Deoxyribonucleic Acid) sequence labeled with biotin points, and c. a DNA sequence with a coding beta-globulin, the probe is SEQ ID Nos: 1-12, the DNA sequence labeled with the biotin points is SEQ ID No.13, and the DNA sequence with the coding beta-globulin is SEQ ID No.14 as an internal locus of control; and the primer includes a first primer used for amplifying 16S rRNA conserved sequences of a majority of common bacteria, a second primer used for amplifying 23S rRNA conserved sequences of the bacteria, and a third primer used for amplifying the internal locus of control, DNA sequences of first primer are SEQ ID Nos: 15-17, DNA sequences of the second primer are SEQ ID Nos.18-19, and DNA sequences of the third primer are SEQ ID Nos.20-21. The genetic testing kit for the infected bacteria in the cerebrospinal fluid, disclosed by the invention, can be used for quickly and accurately detecting 10 common bacteria in the cerebrospinal fluid, and has an important significance in correctly diagnosing and treating an intracranial infector in time.

The invention discloses a short-chain nucleotide aptamer with high specificity and high affinity of beta-microglobulin and a screening method of the aptamer. The nucleotide aptamer provided by the invention comprises DNA (deoxyribonucleic acid) segments of nucleic acids shown by any one from a sequence 1 to a sequence 10. The preparation method of the nucleotide aptamer comprises the steps of designing and synthesizing a random single-chain nucleotide library, and screening the nucleotide aptamer of the beta-microglobulin. The nucleic acid aptamer disclosed by the invention is used for identifying a combined target, so that the nucleic acid aptamer is favorable for rapid determination of the beta-microglobulin.

The invention discloses a typing detection kit for Candida albicans. The typing detection kit comprises a gene chip and various primers. The gene chip is provided with 13 different types of nucleotide sequence probes for the Candida albicans, a DNA sequence marked with biotin points and a DNA sequence with a coding beta-globulin part, wherein the probes are in the sequences of SEQ ID Nos: 1-13 or sequences complementary with the SEQ ID Nos: 1-13, the DNA sequence with the biotin points is SEQ ID No. 14, and the DNA sequence with the coding beta-globulin part is SEQ ID No. 15. The various primers are in the sequences of SEQ ID Nos: 16-21. By means of the typing detection kit for the Candida albicans, a typing joint detection platform for detecting the Candida albicans is provided, synchronous joint detection can be achieved, the detection of specificity can be enhanced, the cost can be lowered, the detection time can be shortened, and the typing detection kit has great significance for carrying out clinic early diagnosis and population screening for the Candida albicans.

The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a polypeptide capable of co-localizing a beta-2 microglobulin component of a MHC class I molecule with an intracellular signalling domain within the cell.

The invention relates to a novel anti-human beta2-microglobulin antibody and application thereof, and belongs to the field of immunochemistry. Various antibodies are prepared by the invention, matching screening is performed, and an antibody combination (BM12 and BM17) with the sensitivity and the specificity meeting the requirements is obtained; meanwhile, the mass production is convenient; the requirements of large-scale clinic application in future can be met. The antibody combination is subjected to detection system debugging and optimization work to achieve the effect of simple and convenient operation. The industrialized application of colloidal gold rapid test paper card of human beta2-microglobulin with the sensitivity, specificity and relevant detection performance meeting the requirements of human-clinic sample detection can be realized.

The invention relates to a novel anti-human beta2-microglobulin antibody and application thereof, and belongs to the field of immunochemistry. Various antibodies are prepared, paired and screened, andthe antibody combination (BM12 and BM17) is obtained, wherein the sensitivity and the specificity of the antibody combination can meet requirements. Mass production is facilitated, and future requirements of large-scale clinical application can be met. The antibody combination is subjected to debugging and optimizing of a detection system, and industrial application of collaurum rapid test papercards of human beta2-microglobulin is obtained, wherein the collaurum rapid test paper cards are convenient to operate, and the sensitivity, the specificity and correlation detection performance of the collaurum rapid test paper cards can meet human clinical sample detection.

The application discloses a recombinant lentivirus vector for treating beta-globulin afunction, a preparation method and application. A gene element of the recombinant lentivirus vector disclosed by the application is composed of a left side lentivirus long terminal repeat, a lentivirus counter-response element, a center poly-purine sequence, a gene locus regulating and controlling sequence of a beta-globulin gene, a beta-globulin gene, of which 87-th threonine is mutated into glutamine, and a right side lentivirus long terminal repeat which are connected in order. According to the recombinant lentivirus vector disclosed by the application, through optimizing and improving the gene element, the gene transduction efficiency is increased, and the beta-globulin gene can be efficiently expressed during erythroid differentiation of hemopoietic stem cells, so that the consumption of viruses can be effectively lowered, and the treatment cost is reduced while the safety is improved. The recombinant lentivirus vector disclosed by the application provides a novel treatment tool and scheme for beta-thalassemia and sickle cell anemia caused by the beta-globulin afunction.

The invention belongs to the technical field of stem cell culture, and particularly relates to an adipose-derived stem cell serum-free culture medium and a preparation method thereof. The adipose-derived stem cell serum-free culture medium provided by the invention comprises a basal culture medium, beta globulin, L-arginine, a bactericide, type III collagen and a cell attachment factor. The adipose-derived stem cell serum-free culture medium provided by the invention can prolong the liquid change time, is high in cell collection rate, is high in purity of finally cultured cells, contains few components, reduces the production cost, and is convenient for subsequent deep research on adipose-derived stem cells.

The invention discloses a method for determining the content of beta2-microglobulin. The method comprises the following steps: 1, preparing a test solution; the method comprises the following steps: taking 1ml of a sample, putting the sample into a 100ml measuring flask, adding a 6mol/L urea solution to a scale, standing at room temperature for 1 hour, and filtering by using a 0.45 mu m filter membrane, thereby obtaining the target product. 2, preparing a reference substance solution; the method comprises the following steps: taking a proper amount of a beta 2-microglobulin reference substance, putting the reference substance into a 100ml measuring flask, adding a 6mol/L urea solution to a scale, and standing at room temperature for 1 hour, so that each 1ml of the prepared solution contains 10mu g of beta 2-microglobulin; step 3, determining according to a high performance liquid chromatography; according to the present invention, the high performance liquid chromatography is adopted to perform determination, such that the beta 2-microglobulin result in the urine and the peritoneal effusion of the patient can be rapidly and conveniently determined, the important significance is provided for the monitoring of the beta 2-microglobulin in the patient body, and the important significance is provided for the artificial kidney research and development.

The present invention provides beta2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

The invention discloses an alpha1 microglobulin trace detection method, and relates to the technical field of biological detection methods. The method comprises the following steps: mixing a reagent a with a sample, adding a reagent b, and carrying out mixed incubation; adding a reagent c for mixing, and reading an absorbance value; after timing reaction, reading the absorbance value again; calculating the difference value of the two absorbance values, making a regression equation function curve of the difference value to the concentration of the alpha1 microglobulin, and substituting the difference value of the sample to be detected into the function curve to calculate the concentration of the alpha1 microglobulin; the reagent a comprising polyethylene glycol and sodium zinc ethylene diamine tetraacetate; the reagent b comprising polyvinylpyrrolidone and sodium chloride; the reagent c comprising polystyrene nanoparticles only marked with an alpha1 microglobulin monoclonal antibody and polystyrene nanoparticles only marked with an alpha1 microglobulin polyclonal antibody. According to the method, loss of alpha1 microglobulin in the sample in the detection process is effectively reduced, detection errors are reduced through specific reagent use and proportion adjustment, and sensitivity is improved.

The invention discloses a preparation method of an ELISA detection kit for detecting the content of a bovine whey component in formula goat milk powder. According to the invention, a cow milk globulin polyclonal antibody prepared and purified by a conventional method is used as a coating antibody, a hybridoma cell 1-beta which is developed by the invention and can secrete a monoclonal antibody capable of specifically recognizing beta-lactoglobulin is used for preparing a monoclonal antibody (as a detection antibody), a sandwich ELISA detection method is established, and the kit is assembled; the lowest detection limit of the kit is 0.25 ng/ml.